Sublingual fentanyl sprays which are marketed and sold by Insys Therapeutics, Inc. have come under investigation recently. The pain medication is used in cancer patients and listed as a Schedule II controlled substance. Insys Therapeutics is under investigation for paying and providing improper benefits to doctors who were prescribing the drug. Insys has in the […]